Login
$STXS
$0.80 -$0.00 (0.34%) Pre-market

$STXS SEC Filings

Filed On Filing
16 Nov 2026 10-Q
12 Nov 2026 SCHEDULE 13D/A
12 Nov 2026 Form 4: Dafna Capital Management Llc, 10% owner and 1 other

Acquired 0 Convertible Promissory Notes (Open Market Purchase)

12 Nov 2026 Form 4: Fischel Nathan, Director

Acquired 0 Convertible Promissory Notes (Open Market Purchase)

10 Nov 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more

St. Louis, November 10, 2026 (Globe Newswire) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates and financial results for the th...

19 Aug 2026 SCHEDULE 13G
13 Aug 2026 EFFECT
13 Aug 2026 EFFECT
13 Aug 2026 424B3
13 Aug 2026 424B3
12 Aug 2026 10-Q
11 Aug 2026 8-K: Results of Operations and Financial Condition

Robotic catheter revenue surpasses $1M in the quarter, growing 270% sequentially

16 Jul 2026 8-K: Other Events

We may be unable to successfully integrate Robocath into our business and may fail to realize any or all of the anticipated benefits of the acquisition, or those benefits may take longer to realize than expected.

15 Jul 2026 S-3
15 Jul 2026 S-3
09 Jul 2026 8-K: Unregistered Sales of Equity Securities; Regulation FD Disclosure +1 more

St. Louis, USA & Rouen, France, July 9, 2026 (Globe Newswire) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has completed its previo...

01 Jul 2026 Form 4: Shamir Nachum, Director

Received 43,103 shares as a grant or award

01 Jul 2026 Form 4: Benfer David, Director

Received 43,103 shares as a grant or award

01 Jul 2026 Form 4: Levin Ross B, Director

Received 43,103 shares as a grant or award

01 Jul 2026 Form 4: Curet Myriam, Director

Received 43,103 shares as a grant or award

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support